Navigation Links
Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution
Date:4/14/2008

ALLEGAN, Mich., April 14 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Children's Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1mg/mL.

The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare's Children's Zyrtec(R) Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and hives relief. According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the last 12 months ending December 2007 were approximately $80 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers."

The Company expects to begin shipping the product immediately.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research entitled "Brain Computer Interface Market - ... 2016 - 2024," the  global brain computer interface (BCI) market ... by 2024. The market is estimated to expand at ... from 2016 to 2024. A BCI device ...
(Date:5/4/2016)... , May 4, 2016  It,s time for an upgrade. There are many ... a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and ... well as a world class manufacturer of innovative technology.  Photo - ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... ... Liposuction specialist Marcia V. Byrd, MD spoke last month at the Fat Disorders ... Airport Hotel. This year’s conference was titled “Living with Lipedema and Dealing with Dercum’s ... treating Lipedema. Dr. Byrd is considered one of the leading physicians in the country ...
(Date:5/5/2016)... ... 05, 2016 , ... Linfield College Online and Continuing Education is encouraging registered ... $50 application fee for all qualified applicants from May 1–14. Students need only go ... when applying . , With the RN to BSN degree program, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Nepenthe Laboratory Services (NLS), a premier ... week to raise non-perishable food item donations for Food for Lane County, and to ... NBC. , “The goal of the assembly was to create an exciting atmosphere for ...
(Date:5/5/2016)... , ... May 05, 2016 , ... In the midst ... to forget the most important arrangement — planning a safe way of getting home ... popular tequila drinks. Unfortunately, these celebrations often lead to drunk drivers on the roads ...
(Date:5/5/2016)... ... , ... Augusta Public Schools has teamed with CareDox to provide confidential and ... offices to streamline and bolster care for district students. , Augusta School District, ... schools serve 2,300 students among its six schools. , Monica Guilliams, BSN, RN, ...
Breaking Medicine News(10 mins):